The Impact of a Dermatology Department on Basal Cell Carcinoma Diagnoses

Nevoid basal cell carcinoma syndrome (NBCCS), also named Gorlin syndrome, is a rare multisystem genetic disorder characterized by marked predisposition to basal cell carcinomas (BCCs), childhood medulloblastomas, maxillary keratocysts, celebral calcifications, in addition to various skeletal and soft tissue developmental abnormalities. Mutations in the tumor suppressor gene PATCHED1 (PTCH1) have been found to be associated in the majority of NBCCS cases. PATCH1 somatic mutations and loss of heterozygosity are also very frequent in sporadic BCCs. Unlike non-syndromic patients, NBCCS patients develop multiple BCCs in sun-protected skin area starting from early adulthood. Recent studies suggest that dermo/epidermal interaction could be implicated in BCC predisposition. According to this idea, NBCCS fibroblasts, sharing with keratinocytes the same PTCH1 germline mutation and consequent constitutive activation of the Hh pathway, display features of carcinoma-associated fibroblasts (CAF). This phenotypic traits include the overexpression of growth factors, specific microRNAs profile, modification of extracellular matrix and basement membrane composition, increased cytokines and pro-angiogenic factors secretion, and a complex alteration of the Wnt/β-catenin pathway. Here, we review studies about the involvement of dermal fibroblasts in BCC predisposition of Gorlin syndrome patients. Further, we matched the emerged NBCCS fibroblast profile to those of CAF to compare the impact of cell autonomous “pre-activated state” due to PTCH1 mutations to those of skin tumor stroma.

Download Full-text

The Impact of Neoadjuvant Hedgehog Inhibitor Therapy on the Surgical Treatment of Extensive Basal Cell Carcinoma

Annals of Plastic Surgery ◽

10.1097/sap.0000000000000452 ◽

2015 ◽

Vol 74 ◽

pp. S193-S197 ◽

Cited By ~ 5

Author(s):

Jessica A. Ching ◽

Heather L. Curtis ◽

Jonathan A. Braue ◽

Ragini R. Kudchadkar ◽

Tania I. Mendoza ◽

...

Keyword(s):

Surgical Treatment ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Inhibitor Therapy ◽

The Impact ◽

Hedgehog Inhibitor

Download Full-text

How patients experience being diagnosed with skin-cancer: Comparative analysis between basal cell carcinoma and relapse-free melanoma. Results of “Objectifs Peau-Cancers Cutanés,” a French study evaluating the impact and management of skin cancer

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.808 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB220

Keyword(s):

Comparative Analysis ◽

Skin Cancer ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

French Study ◽

Cancers Cutanés ◽

Patients Experience ◽

The Impact

Download Full-text

Advanced basal cell carcinomas of the face: A Moroccan series

Our Dermatology Online ◽

10.7241/ourd.20212.6 ◽

2021 ◽

Vol 12 (2) ◽

pp. 135-139

Author(s):

Sara Elloudi ◽

Aida Oulehri ◽

Hanane Baybay ◽

Zakia Douhi ◽

Fatima Zahra Mernissi

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Rural Areas ◽

University Hospital ◽

Temporal Region ◽

Dermatology Department ◽

Skin Malignancy ◽

The Face ◽

The University

Background: Basal cell carcinoma (BCC) is the most common cutaneous skin malignancy. 85% of BCCs affect the face, a region particularly rich in noble organs. Although BCC progresses slowly, considerable local destruction and mutilation may be observed. Material and Methods: We performed a retrospective review of the database stored by our institution. All patients with histologically confirmed mutilating basal cell carcinoma of the face hospitalized at the dermatology department of the university hospital in Fez, Morocco, from 2015 through 2020 were evaluated. Results: Nine patients were included, with the tumors located in the lips, temporal region, orbital region, and cheeks, with sizes varying from 5 to 11 cm. Conclusion: In the series, we were able to highlight the high-risk character of the subpopulation living in rural areas and the role of smoking as a major risk factor.

Download Full-text

Impact of some constitutional characteristics on the development of basal cell carcinoma

Vojnosanitetski pregled ◽

10.2298/vsp0706375r ◽

2007 ◽

Vol 64 (6) ◽

pp. 375-379 ◽

Cited By ~ 1

Author(s):

Milena Raznatovic ◽

Natasa Maksimovic ◽

Janko Jankovic ◽

Davor Music

Keyword(s):

Skin Cancer ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Sun Exposure ◽

Control Group ◽

Hair Color ◽

Preventive Action ◽

Dermatology Department ◽

Fair Skin

Background/Aim. Basal cell carcinoma (BCC) is the most common form of skin cancer in the white population. Increasing incidence of BCC imposes the requirement to identify the risk factors due to eventual preventive action. The aim of this study was to assess the role of some constitutional characteristics in development of BCC among the Montenegrin population. Methods. A case-control study was conducted at the Dermatology Department of Clinical Center of Montenegro in Podgorica from 2002?2003. The study group included 100 histopatologically confirmed BCC cases, while the control group consisted of 100 patients from the same department, who did not present skin cancer and who were individually matched to the cases by sex and age (?5 years). All participants were interviewed using an epidemiological questionnaire. For statistical analysis t test and McNemar ?2 test for matched pairs and multivariate logistic regression analyses were used. Results. The risk for development of BCC was increased among the persons with lighter hair color (t = 4.63; df = 99; p < 0.001), fair skin (t = 2.37; df = 99; p = 0.020), lighter eyes color (t = 2.86; df = 99; p = 0.005), with nevuses (OR = 13.13; p = 0.025; 95% IP = 1.39-12.03), and among those whose skin tone after sun exposure remained light (OR = 3.14; p = 0.001; 95%IP = 1.59-6.18). Conclusion. Our study confirmed the significance of constitutional characteristics such as lighter hair color, fair skin, lighter eyes color, and the presence of nevuses in the development of BCC. .

Download Full-text

Basal Cell Carcinoma Pathology Requests and Reports Are Lacking Important Information

Journal of Skin Cancer ◽

10.1155/2019/4876309 ◽

2019 ◽

Vol 2019 ◽

pp. 1-5 ◽

Cited By ~ 1

Author(s):

Firas Al-Qarqaz ◽

Khaldon Bodoor ◽

Awad Al-Tarawneh ◽

Haytham Eloqayli ◽

Wisam Al Gargaz ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Medical History ◽

Basal Cell ◽

Perineural Invasion ◽

Surrounding Tissue ◽

Depth Of Invasion ◽

Dermatology Department ◽

Excision Margins ◽

Pathology Reports

Introduction.Basal cell carcinoma (BCC) is the most common cancer affecting humans. Luckily it has negligible risk for metastasis; however it can be locally destructive to surrounding tissue. The diagnosis of this tumor relies on clinical and dermoscopic features; however confirmation requires biopsy and histologic examination. Based on clinical and pathologic findings, BCC is classified as low or high risk subtype. The clinician requesting pathology examination for BCC should provide the pathologist with detailed information including patient details, relevant clinical and medical history, site and type of the biopsy, and whether this is a primary or recurrent lesion. The pathologist on the other hand should write an adequate report containing a minimum of core set of parameters including type of BCC, depth of invasion, presence of lymphovascular or perineural invasion, and the excision margins.Objectives.The objective of this study is to evaluate whether requests by clinicians and pathology reports of BCC are adequate.Methods.This is a retrospective analysis done at the dermatology department, faculty of medicine at Jordan University of Science and Technology, Irbid, Jordan. Reports for the period from January 2003 to December 2017 were retrieved and analyzed for data completeness.Results.Most clinical request forms of BCC provided by clinicians are inadequate and lack important relevant information especially in regard to lesion history, patient medical history, and whether BCC is a primary or a recurrent one. Pathology reports for BCC cases also have significant deficiency especially in describing the histologic subtype, depth of invasion, and presence of lymphovascular and perineural invasion. However, the tumor excision margins are adequately described in almost all reports.Conclusions.The study shows that clinicians do not provide adequate clinical information when submitting a request for histopathologic examination of BCC. Similarly, pathologists write incomplete reports that lack important pathologic features. Having pre-set forms (electronic proforma) can help overcome missing information.

Download Full-text

ULTIMATUM – EXCISION OR DIVORCE: THE IMPACT OF A ‘SIMPLE’ BASAL CELL CARCINOMA (BCC)

10.26226/morressier.578e3b51d462b802923829fc ◽

2016 ◽

Author(s):

Rebecca Ball

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

The Impact

Download Full-text

Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center

Journal of Cutaneous Medicine and Surgery ◽

10.1177/12034754211051234 ◽

2021 ◽

pp. 120347542110512

Author(s):

Justin Tong ◽

Brandon Mitchell ◽

Kathryn Roth ◽

Diane Logan ◽

Scott Ernst

Keyword(s):

Basal Cell Carcinoma ◽

Adverse Effects ◽

Cell Carcinoma ◽

Basal Cell ◽

Treatment Duration ◽

Locally Advanced ◽

Maximal Response ◽

Number Of Patients ◽

The Impact ◽

Advanced Basal Cell Carcinoma

Background Vismodegib is a novel Hedgehog pathway inhibitor that has revolutionized the treatment of patients with advanced basal cell carcinoma (BCC) who are poor candidates for surgery or radiation. Few studies have explored the use of vismodegib to facilitate further surgery or radiotherapy, and the optimal treatment duration to balance outcomes with adverse effects. Objectives To characterize the disease response, progression, and recurrence outcomes of BCC patients, and to report the impact of subsequent therapies. Methods We performed a retrospective study of 46 adult patients with advanced basal cell carcinoma (aBCC), including both locally advanced (laBCC) and metastatic (mBCC) disease, treated with vismodegib at a single center from 2012 to 2019. Results Thirty-six had laBCC, and 10 had mBCC. Treatment was given over a mean of 21.9 months. Twenty-three (50%) had a complete response (CR), and 19 (41.3%) achieved partial response (PR). Median time to maximal response was 5.3 months. Eleven (23.9%) had resected disease at median 17.2 months, and 11 patients (23.9%) received radiotherapy. Thirty-two (69.6%) experienced progressive disease after achievement of CR or PR. Among 17 CR patients, who stopped treatment, 14 (82.3%) experienced subsequent relapse; 6 (85%) attained a repeat response. Twenty (43.5%) discontinued treatment at least once due to adverse effects. Conclusions With a response rate of 91%, London Regional Cancer Center’s (LRCP)’s experience with vismodegib supports its effectiveness in treatment of aBCC. Moreover, a significant number of patients treated with vismodegib became amenable to surgery or radiotherapy. Toxicity remained an important factor that limited treatment duration.

Download Full-text